eHealth beats FY2022 guidance; Q4 net income $20.7M vs loss year ago

eHealth, Inc.

2022-FY EPS reported -$4.36 revenue$405,356,000

Q4 revenue $196.3M; GAAP net income $20.7M (10.5% margin) vs net loss $32.2M in Q4 2021.
Adjusted EBITDA $49.5M (25% margin), up 76% YoY from $28.1M in Q4 2021.
FY2022 net operating cost savings of $114M vs FY2021; Medicare segment profit margin 29% vs 15%.
2023 guidance: midpoint revenue growth ~6%; GAAP net loss ~$45M; adjusted EBITDA improvement ~$37M.
Ended FY2022 with $144.4M in cash, cash equivalents and marketable securities.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

eHealth, Inc. reported FY 2023 results: net income roughly $45.0 million net loss. Guidance initiated.

Period: FY 2023
Net income: roughly $45.0 million net loss
Guidance: initiated
Result: guidance update

Exact text from the filing

Midpoint of 2023 annual guidance implies return to revenue growth at 6% while achieving GAAP net loss of roughly $45.0 million and year-over-year improvement in adjusted EBITDA of roughly $37.0 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

eHealth, Inc. reported Q4 2022 results: revenue $196.3M, net income $20.7M.

Period: Q4 2022
Revenue: $196.3M
Net income: $20.7M
Result: reported results

Exact text from the filing

Fourth Quarter 2022 Overview $196.3M $20.7M $49.5M TOTAL REVENUE GAAP NET INCOME ADJUSTED EBITDA (1) $(18.6)M 25% YoY $144.4M OPERATING CASH FLOW IMPROVEMENT TO TELEPHONIC CONVERSION RATE ENDING CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

eHealth, Inc. filing history →

Source: SEC EDGAR

accession 0001333493-23-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.